Product Description
Mechanisms of Action: ER Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/15/2024 |
PubMed |
Doxycycline-Mediated Inhibition of Snake Venom Phospholipase and Metalloproteinase. |
|
05/15/2024 |
PubMed |
Characterization of the role of Facebook groups for patients who use scalp cooling therapy: a survey study. |
|
05/01/2024 |
PubMed |
Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt. |